Mesoblast Limited (MSB) – Company Press Releases
-
Mesabi Trust Press Release
-
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Ste
-
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
-
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
-
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
-
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
-
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
-
United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
-
Mesabi Trust Press Release
-
Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
-
Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD
-
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023
-
Mesabi Trust Press Release
-
Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee
-
Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval
-
Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023
-
Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children
-
Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023
-
Mesabi Trust Press Release
-
Coya Therapeutics (“Coya”) Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner
-
Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role
-
Mesabi Trust Press Release
-
Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023
-
Mesoblast Financial Results and Corporate Update Webcast
-
Appendix 4C Quarterly Activity Report
-
Mesoblast Completes Private Placement
-
Mesabi Trust Press Release
-
FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing
-
FDA Accepts Mesoblast’s Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Da
-
Mesoblast Reports Operational and Financial Highlights for Quarter Ended December 31, 2022
-
DREAM-HF Phase 3 Trial Results for Mesoblast Cell Therapy in Heart Failure Published in Journal of the American College of Cardiology (JACC)
-
Mesoblast Financial Results and Corporate Update Webcast
-
Remestemcel-L Clinical and Potency Studies Presented at Premier Meeting of Transplantation Research and Therapy
-
FDA Grants Regenerative Medicine Advanced Therapy (Rmat) Designation for Rexlemestrocel-L in Chronic Low Back Pain
-
Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)
-
Appendix 4C Quarterly Activity Report
-
Mesabi Trust Press Release
-
Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches of Financing Facility
-
Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
-
Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022
-
Mesoblast Financial Results and Corporate Update Webcast
-
Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022
-
Mesabi Trust Press Release
-
Mesoblast Submits New Information to FDA IND File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD
-
Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022
-
Mesoblast Corporate Update and Financial Results Webcast
-
Jane Bell Joins Mesoblast Board
-
Appendix 4C Quarterly Activity Report
-
Mesabi Trust Press Release
-
Rexlemestrocel-L to be Highlighted at Maxim’s Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management
Back to MSB Stock Lookup
